685 results about "IV Chemotherapy" patented technology

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present disclosure relates to a herbo-mineral kit for alleviating adverse effects of chemotherapy resulting into improved quality of life of patients. The herbo-mineral kit comprises a first container containing Padmakadi Ghrut (PDG) in a thick, viscous form; a second container containing Mouktikyukta Kamdudha Vati (MKD) in a solid dosage form; a third container containing Praval Pishti Vati (PPV) in a solid dosage form; and a fourth container containing Ananta vati in a solid dosage form. The herbo-mineral kit of the present disclosure can be used for alleviating adverse effects of chemotherapy such as nausea, vomiting, constipation, diarrhea, stomatitis, and skin discoloration in cancer treatment. Use of the herbo-mineral kit of the present disclosure may prove to be beneficial in all types of cancers and diseases for which chemotherapy is treatment of choice.

Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

The invention relates to a core-shell structure drug-loaded magnetic-thermal hydrogel microsphere for treating drug-resistant ovarian cancer and a preparation method thereof, belonging to the field of biological and medical micro-nano materials and technologies, and the core-shell structure drug-loaded magnetic-thermal hydrogel microsphere is formed by combining an inner core and a shell layer through covalent crosslinking and electrostatic interaction. An anti-tumor drug cis-platinum and magnetic nanoparticles are loaded on an inner core, and an AZ191 inhibitor is loaded on a chitosan shell, so that preferential release of AZ191 is realized to inhibit a drug-resistant signal channel and reduce the drug resistance of cancer cells, and the cis-platinum is slowly released after the action is completed to kill tumor cells. And the magnetic nanoparticles in the inner core can be heated under an external magnetic field, so that multifunctional synergistic treatment of magnetic hyperthermia, drug resistance inhibition and chemotherapy is realized. Chitosan and sodium alginate are biodegradable materials, so that the utilization rate of the embedded medicine can be increased, and meanwhile, the medicine can be metabolized out of a body. The preparation method does not relate to toxic cross-linking agents and organic solvents, and the prepared hydrogel core-shell microspheres have no biotoxicity. Complicated operation steps are not needed, the technological process is simple, the preparation period is short, and the application range is wide.

The present invention relates to nitrogen-containing derivatives of salinomycin having the formula (I), as well as pharmaceutically acceptable salt thereof, and synthesis and uses thereof, in particular for the treatment and / or prevention of cancer including for preventing cancer metastasis and / or for preventing cancer recurrence and / or for decreasing resistance to a chemotherapy in a subject.

A hybrid liver cancer prognosis model, prognosis system and medium, the model takes independent influence factors as input and outputs hybrid liver cancer postoperative risk scores, the hybrid liver cancer postoperative risk scores are used for dividing risk levels, and the risk levels are used for hybrid liver cancer prognosis evaluation. And / or is used for postoperative adjuvant chemotherapy decision-making of mixed liver cancer. The hybrid liver cancer prognosis model is jointly constructed by combining the traditional clinical pathological characteristics and immune microenvironment indexes, the key effect of the tumor immune microenvironment in CHC prognosis is indicated, and the constructed hybrid liver cancer prognosis model has good CHC prognosis prediction performance; in addition, decisions of postoperative adjuvant chemotherapy can be provided for patients with different risk levels, precise treatment of the CHC patients is achieved, and long-term survival prognosis of the CHC patients is improved.

The invention discloses a gastric cancer postoperative chemotherapy dynamic intervention method and system based on time point matching, and relates to the technical field of postoperative intervention. Health state data of wearable medical equipment of a gastric cancer postoperative patient is collected; preliminarily dividing the stomach cancer postoperative chemotherapy cycle into a plurality of key physiological time points based on the symptom inflection points, and respectively matching an intervention core problem and a corresponding stomach cancer postoperative chemotherapy intervention scheme for the plurality of key physiological time points; and the postoperative intervention platform analyzes the time period health state data collected by the wearable medical equipment at set time intervals, analyzes the health state data to automatically identify gastric cancer postoperative symptom inflection points, and dynamically matches key physiological time points based on symptom inflection point results. The stomach cancer postoperative treatment disruption rate is reduced, the crisis inflection point recognition accuracy is greatly improved, and the bone marrow suppression early diagnosis rate is greatly improved; the early diagnosis rate of postoperative wound infection of gastric cancer is improved, unnecessary intervention is reduced, and crisis event treatment is accelerated.

The invention discloses an application of indolepropionic acid in preparation of a medicine for preventing or treating ovarian cancer, the medicine takes indolepropionic acid as an active ingredient, the concentration is 0.1-1000 mu M, and the dosage forms comprise tablets, capsules, granules, pills, gels, suppositories, ointments, emulsions, mixtures, suspensions, injections and solutions. Administration routes comprise oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration, and can be combined with chemotherapeutic drugs for use. It is found through experiments that IPA with different concentrations can inhibit cell growth of ovarian cancer cell lines SKOV3 and A2780, cell proliferation of macrophages RAW264.7 is remarkably promoted, and the IPA has a potential immune promotion effect and good biological safety. In addition, the IPA can enhance the sensitivity of chemotherapeutic drugs, and the IPA and the chemotherapeutic drugs are combined to be applied to treatment of ovarian cancer, so that the treatment effect of the drugs can be remarkably improved.

The invention discloses a leukemia chemotherapy patient intravenous drug extravasation protection device, and relates to the technical field of medical apparatuses and instruments, the leukemia chemotherapy patient intravenous drug extravasation protection device comprises a monitoring fluid break assembly, the monitoring fluid break assembly comprises an infusion table and two side plates, the two side plates are symmetrically and fixedly connected to the two sides of the infusion table, and the top ends of the sides, away from each other, of the two side plates are each fixedly connected with a square column; the two square columns are each connected with a sliding plate in a sliding mode, and the surfaces of the two square columns are each sleeved with a first spring. Intravenous medicine exosmosis of a patient is monitored through the absorbent paper, a subsequent structure is triggered, medicine circulation in the infusion tube is cut off, intravenous infusion can be stopped at the first time, and the situation that the patient cannot find medicine exosmosis in time, and consequently chemotherapy medicine is continuously exosmosis, and the chemotherapy effect is affected is prevented. The problem that the skin necrosis range of the exosmosis part is further expanded is solved, the effect of stopping the chemotherapy medicine can be achieved, and waste of the chemotherapy medicine is avoided.

According to the PDA in-situ polymerization drug perfusion delivery system provided by the invention, the interaction relationship of a perfusion drug system on an organism signal channel and immune response is studied; through manganese metal immunoregulation, based on copper death synergistic therapy, novel protein drug immunotherapy and enhancement of the inhibition action mechanism of traditional chemotherapy on bladder cancer cells, various drugs are organically combined by utilizing dopamine-mediated in-situ bladder intracavity polymerization loaded drugs and combining with the characteristics of polydopamine, so that the bladder cancer cell inhibition effect is enhanced, and the bladder cancer cell inhibition effect is enhanced. A novel multi-effect-in-one multifunctional bladder perfusion drug system is formed, the complexity of drug design is simplified, the bioavailability of drugs is improved, and it is ensured that multi-mode collaborative treatment in the bladder is achieved.

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a scrophularia ningpoensis extract for relieving chemotherapy-induced acute kidney injury and application of the scrophularia ningpoensis extract in preparation of a product for relieving chemotherapy-induced acute kidney injury. The preparation method comprises the following steps: putting fresh ginseng into a high-temperature and high-pressure sterilization pot, steaming at 110-120 DEG C for 1-3 hours, taking out, cooling to room temperature, and repeating the steaming cooling process for 2-5 times; and crushing the treated ginseng materials, adding a mixed strain of saccharomyces cerevisiae and lactobacillus plantarum in a mass ratio of 1: 1, fermenting for 24-72 hours, filtering fermentation liquor, and drying filter residues to obtain the black ginseng extract. The cisplatin-induced acute kidney injury is prevented and / or treated by improving oxidative stress and mitochondrial functional activity, reducing the content of lipid peroxide, inhibiting expression of inflammatory factors TNF alpha, IL1beta and COX2 and remarkably reducing the cell apoptosis rate and the level of inflammatory factors related to endoplasmic reticulum stress.

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

The invention provides a multifunctional intelligent anti-thrombus PICC (peripherally inserted central catheter) for tumor chemotherapy, which comprises a catheter body, a catheter tip, a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity, and the first auxiliary cavity and the second auxiliary cavity are arranged around the main infusion cavity to form a spiral structure; a micro pressure sensor array is embedded in the pipe wall of the first auxiliary cavity; a biological impedance measuring electrode pair is embedded in the pipe wall of the second auxiliary cavity; and the micro pressure sensor array, the biological impedance measuring electrode pair, the micro ultrasonic transducer and the temperature sensor are connected with a processor. According to the method, active thrombus prevention is achieved, passive treatment is changed into active prevention through a triple mechanism, and the thrombus occurrence rate is greatly reduced; meanwhile, the tube body is formed by mutually winding, fusing and extruding three independent cavities (a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity) like a DNA double helix (triple helix is provided herein); and the mechanical stimulation and damage to the inner wall of the blood vessel are reduced.

The invention relates to a gastric cancer chemotherapy benefit prediction analysis method and system, and the method comprises the steps: obtaining clinical chemotherapy index data, imaging data and basic index data, and carrying out the standard integration processing, and obtaining a clinical integrated data set; carrying out image structure and basic target extraction on the clinical integrated data set to obtain an image structured feature vector and target feature data; obtaining knowledge graph data, and performing association analysis on the knowledge graph data and the target feature data to obtain a corresponding initial scheme group; performing trend prediction on the clinical integration data set according to the dynamic monitoring data to obtain corresponding dynamic trend information; inputting a preset four-factor joint prediction model to perform effect trend prediction to obtain a corresponding benefit prediction result; and performing overall analysis on the initial scheme group and the benefit prediction result to obtain a corresponding overall benefit information report. According to the method, the data basic integrity of benefit prediction can be improved, and more reliable data support is provided for subsequent analysis.

The invention relates to the field of biological medicine, and discloses application of a biphenyl cyclooctene lignan compound and a chemotherapy sensitizing drug. The biphenyl cyclooctene lignan compound can be used for preparing a chemotherapy sensitizing drug, and the chemotherapy sensitizing drug is an ovarian cancer chemotherapy sensitizing drug, and can improve the sensitivity of cells to paclitaxel and inhibit the activity, proliferation and migration of the cells. The biphenyl cyclooctene lignan compound is combined with paclitaxel, so that the cell activity of the ovarian cancer paclitaxel drug-resistant cell A2780 / Taxol can be remarkably reduced, and the cell survival rate is only 31.13%. The combination of the biphenyl cyclooctene lignan compound and paclitaxel can also be used for preparing chemotherapy sensitizing drugs.

The invention discloses an esophageal cancer local chemotherapy device, and belongs to the technical field of chemotherapy auxiliary equipment, the esophageal cancer local chemotherapy device comprises a sealing device, the sealing device comprises a drug delivery tube, the lower end of the drug delivery tube is fixedly connected with a zigzag mounting tube, and the side wall of the zigzag mounting tube is rotatably connected with a plurality of hinge connecting rods; the lower end of the zigzag mounting tube is fixedly connected with a closed collecting film fixedly connected with the upper ends of the hinge connecting rods, the interior of the zigzag mounting tube is slidably connected with a movable block, and the device can be tightly attached to the inner wall of the esophagus through unfolding of the closed collecting film to form an effective closed structure, so that the position of medicine at the focus is locked, and the medicine is prevented from being damaged. Therefore, the local treatment effect of the medicine can be improved, meanwhile, the medicine is prevented from flowing to the stomach along with natural physiological movement of the esophagus, stimulation to the digestive tract of a patient is reduced, meanwhile, the influence on normal tissue of the patient is reduced, precise treatment is achieved, and the health of the patient is protected to the maximum extent.

The invention discloses a composition for relieving gastrointestinal reaction and enhancing appetite of cancer patients after chemotherapy, and relates to a composition for relieving gastrointestinal reaction and enhancing appetite. The invention aims to solve the problem of strong gastrointestinal reaction of cancer patients after chemotherapy. The composition for relieving gastrointestinal reaction and enhancing appetite after chemotherapy of cancer patients is prepared from ganoderma capense and coriolus versicolor polysaccharide fermentation products, phellinus igniarius polyphenol extracts and phellinus pini and ginseng flower water extracts according to the mass ratio of 1: 1: 1. The composition disclosed by the invention can be used for improving the anti-cancer effect in a mouse body. The traditional Chinese medicine composition not only can improve the immune function of the body and improve appetite, but also can change the immune microenvironment of the body and enhance the immune function of the body. The invention belongs to the technical field of relieving gastrointestinal reactions of cancer patients after chemotherapy.

Disclosed herein are methods of treating an individual having a gastroesophageal cancer, of treating or identifying an individual having gastroesophageal cancer for a treatment, or stratifying individuals having a gastroesophageal cancer for a treatment based on a tumor mutational burden (TMB) score or a TMB score.

The invention discloses a culture system, culture method and application of gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system comprises: a basic culture medium, which is a DMEM / F12 culture medium, and is additionally added with a special growth promoting factor obtained from a natural extract; the multiple growth factors comprise an epidermal growth factor (EGF), a fibroblast growth factor (FGF), a bone morphogenetic protein (BMP) and a vascular endothelial growth factor receptor inhibitor (VEGFRi), and the concentration of each growth factor is accurately screened and optimized; the extracellular matrix is Matrigel modified by physical and chemical methods; the specific additive comprises an antioxidant N-acetylcysteine (NAC). According to the culture system, the culture method and the application of the gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system which is closer to a real environment in vivo is constructed by optimizing basic culture medium components, setting various growth factors and specific additive concentrations and adopting modified Matrigel as an extracellular matrix.

The invention relates to the technical field of gastrointestinal tumor chemotherapy risk assessment, and particularly discloses a gastrointestinal tumor chemotherapy risk scoring model and a construction method thereof, and the method comprises the steps: obtaining the individualized feature data and basic physiological data of a historical patient, and constructing an individualized difference library with a unique ID, and a core influence library; the method comprises the following steps: standardizing and coding double-library data, synchronizing clinical data containing treatment effect codes, forming a data dictionary, acquiring and coding current gastrointestinal tumor patient data, and matching the data dictionary to judge individual difference abnormity; when the first data set is abnormal, constructing a first data set, screening core independent variables through Logistic regression, and constructing a scoring model by using an LSTM (Long Short Term Memory) model; when no abnormity exists, redundant codes are removed to obtain a second data set, and modeling is conducted through the same method. Through double-library linkage and scene-divided modeling, the three-level toxicity risk prediction precision is improved, data support is provided for clinical chemotherapy dose adjustment and toxicity prevention, and the risk of excessive treatment or insufficient treatment is reduced.

The invention provides a solid-liquid phase-change microcapsule cooling cold cap for preventing alopecia in chemotherapy. The solid-liquid phase-change microcapsule cooling cold cap comprises a shell layer, a phase-change cooling layer and a heat-conducting attaching layer, the phase change cooling layer is sealed between the heat conduction bonding layer and the shell layer; the phase change cooling layer comprises a frame and phase change microcapsules; the frame is built between the shell layer and the heat-conducting laminating layer, and the phase change microcapsules are filled between the shell layer and the heat-conducting laminating layer; the phase change microcapsule is a microcapsule encapsulated by a low-temperature solid-liquid phase change material; the solid-liquid phase change material is used as a cooling material, the cooling effect is remarkable, the solid-liquid phase change material is not particularly hard after being frozen, still has a certain deformation space and can be attached to all parts of the head of a patient, medical silica gel is used as the scalp attaching layer, the scalp attaching layer is soft, breathable and good in heat conduction and scalp attaching effect, and the cooling effect is good. The cold cap and the head of the patient are attached more tightly, and the phenomenon that a gap exists between the cold cap and the scalp, and the head anti-falling effect is affected after chemotherapy is avoided.

The utility model belongs to the technical field of medical equipment, and discloses a vomiting relieving treatment device for tumor chemotherapy, which comprises a massage module, a fastening mechanism is arranged on the outer wall of the massage module, and a rolling mechanism is arranged on the outer wall of the massage module; the winding mechanism comprises a winding drum, a partition plate is fixedly connected to the inner wall of the winding drum, a rotating shaft is elastically connected to the outer wall of the partition plate through a volute spiral spring, a clamping groove is formed in the outer wall of the rotating shaft, a fixing block is fixedly connected to the outer wall of the front end of the winding drum, and a limiting block is elastically connected to the inner wall of the fixing block through a connecting spring. The pull-out length of the bandage can be fixed through clamping connection of the limiting block and the clamping groove, limiting of the rotating shaft is removed when the bandage is not used, the bandage can be automatically wound in the winding barrel, space is saved, and the problems that the bandage is wound disorderly due to the fact that the bandage is exposed all the time, and the bandage is inconvenient to tidy in the using process are solved.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.

The utility model discloses a clinical tumor chemotherapy pump portable protective device in the technical field of medical instruments, which comprises a box body and a chemotherapy pump body, the inner side of a sleeve is connected with a connecting rod in a sliding manner, the surface of the connecting rod is fixedly provided with a limiting block, a spring is sleeved on the surface of the connecting rod, the surface of the connecting rod is fixedly provided with a connecting block, and the connecting block is fixedly connected with the box body. One side of the connecting block is fixedly connected with one end of a spring, one end of the connecting rod is fixedly connected with a clamping plate, and one end of the connecting rod is fixedly provided with a connecting plate. Through the arranged box body, the chemotherapy pump body is inserted into the box body to be placed, and the protection effect on the chemotherapy pump body is improved; according to the chemotherapy pump convenient to use, the sleeve, the connecting rod, the limiting block, the spring, the connecting block, the clamping plate and the connecting plate are arranged, so that a chemotherapy pump body in the box body can be conveniently clamped and fixed, the stability of the chemotherapy pump in the using period is improved, and the situation that the chemotherapy pump shakes when a patient moves, and the liquid medicine infusion speed is affected is avoided.

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and / or have relapsed or not responded to a prior chemotherapy.

The invention relates to a tirapazamine-loaded phosphorus-containing dendrimer / protein compound for inducing tumor mineralization as well as a preparation method and application thereof, the compound takes diphosphonate-terminated phosphorus-containing dendrimer AK176 as a carrier, and the carrier is loaded with protein and medicine. The nano-drug can target tumor cells through FN and form a biomineralization layer in the peripheral area of tumor tissues, and a tumor hypoxic microenvironment is intensified, so that the pharmaceutical activity of tirapazamine is activated, and cooperative treatment of blocking treatment / chemotherapy of triple-negative breast cancer is realized.

The present invention provides a cold-stimulus-resistant nursing device after tumor chemotherapy, belonging to the field of nursing appliances. It includes a wrapping member; a heat-conducting pipe is arranged inside the wrapping member, and heat-generating devices are movably connected to both ends of the heat-conducting pipe. The heat-generating device includes an outer housing, and a blowing structure and a heat-adjusting structure are respectively arranged inside the outer housing. A leak-proof structure is connected between the heat-conducting pipe and the outer housing; the blowing structure includes a central shaft rod rotatably connected to the axis of the outer housing, a variable-frequency motor is fixedly connected inside the outer housing, and an output end of the variable-frequency motor is fixedly connected with a first bevel gear. This application can meet the use of people with different heights, generate heat quickly at the same time, form a circulating heating, the heat in each area is more uniform, and the heat can be automatically adjusted according to the wind speed, and the sealing effect of the structure at the connection between the outer housing and the heat-conducting pipe can be automatically adjusted according to the wind speed.